89bio: Promising As Pegozafermin Nears Phase 3 Readout (NASDAQ:ETNB)

Pegozafermin, ETNB's FGF21 analog, shows promise in late-stage trials for MASH & severe hypertriglyceridemia. Key data & potential approval ahead.